ROIVANT SCIENCES LTD. (ROIV) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 7.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $7.53M | (m) | (m) |
| 2026-03-31 | (m) | $8.26M | (m) | (m) |
| 2025-12-31 | (m) | $13.31M | (m) | (m) |
| 2025-09-30 | (m) | $20.33M | (m) | (m) |
| 2025-06-30 | (m) | $23.23M | (m) | (m) |
| 2025-03-31 | (m) | $29.05M | (m) | (m) |
| 2024-12-31 | (m) | $122.58M | (m) | (m) |
| 2024-09-30 | (m) | $129.13M | (m) | (m) |
| 2024-06-30 | (m) | $158.30M | (m) | (m) |
| 2024-03-31 | (m) | $124.80M | (m) | (m) |
| 2023-12-31 | (m) | $123.24M | (m) | (m) |
| 2023-09-30 | (m) | $103.15M | (m) | (m) |
| 2023-06-30 | (m) | $78.58M | (m) | (m) |
| 2023-03-31 | (m) | $61.28M | (m) | (m) |
| 2022-12-31 | (m) | $43.13M | (m) | (m) |
| 2022-09-30 | (m) | $50.42M | (m) | (m) |
| 2022-06-30 | (m) | $51.87M | (m) | (m) |
| 2022-03-31 | (m) | $55.29M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $23.80M | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |